Cleavage of the Matricellular Protein SPARC by Matrix Metalloproteinase 3 Produces Polypeptides That Influence Angiogenesis*

SPARC, a matricellular protein that affects cellular adhesion and proliferation, is produced in remodeling tissue and in pathologies involving fibrosis and angiogenesis. In this study we have asked whether peptides generated from cleavage of SPARC in the extracellular milieu can regulate angiogenesis. Matrix metalloproteinase (MMP)-3, but not MMP-1 or 9, showed significant activity toward SPARC. Limited digestion of recombinant human (rhu)SPARC with purified catalytic domain of rhuMMP-3 produced three major fragments, which were sequenced after purification by HPLC. Three synthetic peptides (Z-1, Z-2, and Z-3) representing motifs from each fragment were tested in distinct assays of angiogenesis. Peptide Z-1 (3.9 kDa, containing a Cu2+-binding sequence KHGK) exhibited a biphasic effect on [3H]thymidine incorporation by cultured endothelial cells and stimulated vascular growth in the chick chorioallantoic membrane (CAM). In contrast, peptides Z-2 (6.1 kDa, containing Ca2+-binding EF hand-1) and Z-3 (2.2 kDa, containing neither Cu2+-binding motifs nor EF hands), inhibited cell proliferation in a concentration-dependent manner and exhibited no effects on vessel growth in the CAM. Reciprocal results were obtained in a migration assay in native collagen gels: peptide Z-1 was ineffective over a range of concentrations, whereas Z-2 or Z-3 stimulated cell migration. Therefore, proteolysis of SPARC by MMP-3 produced peptides that regulate endothelial cell proliferation and/or migration in vitro in a mutually exclusive manner. One of these peptides containing KHGK also demonstrated a concentration-dependent effect on angiogenesis.

[1]  J. Davidson,et al.  SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. , 2003, The Journal of investigative dermatology.

[2]  E. Sage,et al.  SPARC-null mice exhibit increased adiposity without significant differences in overall body weight , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Hughes,et al.  Thrombospondin-1 differentially induces chemotaxis and DNA synthesis of human venous smooth muscle cells at the receptor-binding level , 2002, Journal of Cell Science.

[4]  Z. Werb,et al.  New functional roles for non-collagenous domains of basement membrane collagens , 2002, Journal of Cell Science.

[5]  P. Bornstein,et al.  Matricellular proteins: extracellular modulators of cell function. , 2002, Current opinion in cell biology.

[6]  Takanori Aoki,et al.  Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.

[7]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[8]  H. Lijnen,et al.  Matrix Metalloproteinase Inhibition Impairs Adipose Tissue Development in Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  F. Lupu,et al.  Persistence of Atherosclerotic Plaque but Reduced Aneurysm Formation in Mice With Stromelysin-1 (MMP-3) Gene Inactivation , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  B. Olsen,et al.  The role of collagen-derived proteolytic fragments in angiogenesis. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[11]  L. Matrisian,et al.  Osteopontin, a Novel Substrate for Matrix Metalloproteinase-3 (Stromelysin-1) and Matrix Metalloproteinase-7 (Matrilysin)* , 2001, The Journal of Biological Chemistry.

[12]  E. Sage,et al.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.

[13]  E. Sage,et al.  Regulation of interactions between cells and extracellular matrix: a command performance on several stages. , 2001, The Journal of clinical investigation.

[14]  J. Murphy-Ullrich.  The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? , 2001, The Journal of clinical investigation.

[15]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[16]  R. Timpl,et al.  Calcium Affinity, Cooperativity, and Domain Interactions of Extracellular EF-hands Present in BM-40* , 2000, The Journal of Biological Chemistry.

[17]  Z. Werb,et al.  The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter , 2000, Oncogene.

[18]  R. Colman,et al.  Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. , 2000, Blood.

[19]  T. Sasaki,et al.  Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. , 1999, Matrix biology : journal of the International Society for Matrix Biology.

[20]  K. Sakaguchi,et al.  Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. , 1999, Blood.

[21]  M. Reed,et al.  Expression of SPARC (Secreted Protein, Acidic and Rich in Cysteine) in Healing Intestinal Anastomoses and Short Bowel Syndrome in Rats , 1999, Digestive Diseases and Sciences.

[22]  H. Kleinman,et al.  Identification of endothelial cell binding sites on the laminin γ1 chain , 1999 .

[23]  E. Sage,et al.  A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices. , 1999, Microvascular research.

[24]  Jean-Michel,et al.  SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. , 1998, Cancer research.

[25]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[26]  P. Parsons-Wingerter,et al.  A novel assay of angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection. , 1998, Microvascular research.

[27]  K. Brew,et al.  Expression of Human Pro-Matrix Metalloproteinase 3 that Lacks the N-terminal 34 Residues in Escherichia coli: Autoactivation and Interaction with Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) , 1998, Biological chemistry.

[28]  E. Ginns,et al.  Mice That Lack Thrombospondin 2 Display Connective Tissue Abnormalities That Are Associated with Disordered Collagen Fibrillogenesis, an Increased Vascular Density, and a Bleeding Diathesis , 1998, The Journal of cell biology.

[29]  U. Shankavaram,et al.  Regulation of human monocyte matrix metalloproteinases by SPARC , 1997, Journal of cellular physiology.

[30]  R. Timpl,et al.  Crystal structure of a pair of follistatin‐like and EF‐hand calcium‐binding domains in BM‐40 , 1997, The EMBO journal.

[31]  R. Timpl,et al.  Recombinant and tissue-derived mouse BM-40 bind to several collagen types and have increased affinities after proteolytic activation , 1997, Cellular and Molecular Life Sciences CMLS.

[32]  R. Timpl,et al.  Limited Cleavage of Extracellular Matrix Protein BM-40 by Matrix Metalloproteinases Increases Its Affinity for Collagens* , 1997, The Journal of Biological Chemistry.

[33]  E. Sage,et al.  Renaturation of SPARC expressed in Escherichia coli requires isomerization of disulfide bonds for recovery of biological activity. , 1996, The international journal of biochemistry & cell biology.

[34]  B. Fox,et al.  Lactose fed-batch overexpression of recombinant metalloproteins in Escherichia coli BL21 (DE3): process control yielding high levels of metal-incorporated, soluble protein. , 1995, Protein expression and purification.

[35]  M. Iruela-Arispe,et al.  Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. , 1995, Molecular biology of the cell.

[36]  E. Sage,et al.  SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin‐like region and the Ca2+‐binding EF‐hand , 1995, Journal of cellular biochemistry.

[37]  M. Folkman,et al.  Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca2+‐binding EF‐hand sequence , 1995, Journal of cellular biochemistry.

[38]  M. Iruela-Arispe,et al.  SPARC is a source of copper-binding peptides that stimulate angiogenesis , 1994, The Journal of cell biology.

[39]  E. Sage,et al.  The biology of SPARC, a protein that modulates cell‐matrix interactions , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  E. Sage,et al.  Specific interaction of SPARC with endothelial cells is mediated through a carboxyl-terminal sequence containing a calcium-binding EF hand. , 1993, The Journal of biological chemistry.

[41]  P. Birembaut,et al.  In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. , 1993, The Journal of clinical investigation.

[42]  Z. Werb,et al.  SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway , 1993, The Journal of cell biology.

[43]  E. Sage,et al.  Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts , 1993, Journal of cellular physiology.

[44]  R. Ross,et al.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Sage,et al.  The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Sage,et al.  Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape , 1990, The Journal of cell biology.

[47]  J. Tam,et al.  A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. , 1988, The Journal of biological chemistry.

[48]  P. Bornstein,et al.  Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. , 1984, The Journal of biological chemistry.

[49]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[50]  R. Ross,et al.  Inhibition of PDGF‐stimulated and matrix‐mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin‐dependent kinase inhibitors , 2002, Journal of cellular biochemistry.

[51]  R. Brekken,et al.  SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[52]  E. Sage,et al.  Expression of biologically active human SPARC in Escherichia coli. , 1996, Archives of biochemistry and biophysics.